The Ultimate Directory on Healthcare Webinars

Today’s pharmaceutical industry is demanding more flexibility in manufacturing. Faced with rapidly evolving patient needs and relentless pressure to bring new drugs to market fast, companies must find ways to swiftly adapt, scale and optimize their production processes. But automation systems are traditionally rigid and expensive to change. To address this growing challenge, the manufacturing facility of the future is modular, using 'plug-and-play' technology to deliver greater versatility without increasing costs or compromising quality. In this webinar, you will find out how modular production based on this groundbreaking new standard is changing the industry for the better. You will also hear from Sebastian Härtner, Lead of Future Manufacturing for Life Science and Chemicals at EMD Electronics (a division of Merck KGaA, Darmstadt, Germany). Sebastian will introduce how these flexible manufacturing practices were implemented at one facility and what they have accomplished as a result. Key learning objectives: Why pharmaceutical companies need flexibility in manufacturing, How modularity is achieved using the Module Type Package (MTP) standard from NAMUR NE 148, How a flexible approach makes planning easier for everything from physical connections to IT/OT cybersecurity, Who is already leveraging modular production, and how it is transforming their business.

Windtree Therapeutics, Inc. is advancing late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock. Windtree's heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree's portfolio is rostafuroxin, a novel precision drug product targeting the treatment resistant hypertension disease state for patients with certain genetic profiles.

In a new webinar, Manatt Health and CMMI will share an in-depth look at the MCP model, including objectives, requirements and participation options. Click to register for the free webinar.

Join us for an insightful conversation on the challenges and solutions of scaling health data connectivity in large organizations. Hear from industry leaders at McKesson, Takeda Pharmaceuticals, and Duke Health as they share their experiences in developing and scaling data connectivity within and across large organizations. This webinar will dive into the complexities of data-sharing strategies, scalability, compliance and privacy, enabling technologies, and what the future can hold for interconnected health data.

Circulating tumor DNA (ctDNA) profiling is increasingly used in solid tumor management to inform a variety of clinical research questions. ctDNA supports non-invasive testing for trial enrollment and longitudinal monitoring. It has potential applications in clinical study design, prognostication, and understanding when de-escalation may be possible.In this seminar, Valsamo Anagnostou of John Hopkins University will discuss implications in assessing ctDNA in advanced cancer given variable shed in patients, as well as considerations in selecting an approach. She will highlight data demonstrating the value of ctDNA dynamics and recently initiated clinical trials leveraging response-adaptive study designs and how this information can support clinical research to guide patient care.Mia Levy, chief medical officer at Foundation Medicine, will present clinical analysis for Foundation Medicine’s ctDNA tumor fraction method and how it can be leveraged for studies using only liquid biopsy to provide confidence in a negative result, support risk stratification, response-adaptive study designs, and dose selection. She will also highlight how the Foundation Medicine portfolio can support clinical studies leveraging ctDNA.The speakers will discuss:ctDNA-driven interventional clinical trials in immune-oncology based on molecular response.Response-adaptive study designs for targeted therapies.Early-phase clinical studies using ctDNA to support dose selection or early go/no go decisions.The clinical insights provided by Foundation Medicine’s ctDNA tumor fraction and portfolio of solutions for supporting clinical research and drug development.

Discover a groundbreaking webinar delving into advancements in antibody-drug conjugates (ADCs) and related patent filings. Antibody-drug conjugates are among the most promising drug classes in oncology...

Join our exclusive webinar on the CMS 2024 Final Transparency Rule! In this informative session, Panacea industry experts will break down the key aspects of the CMS 2024 Final Transparency Rule, providing valuable insights into its implications for healthcare providers. Extend your learning and attend our live 45-minute Q&A session at the end of the webinar. Dive deep into the intricacies of the 2024 Final Transparency Rule with our experts. Ask targeted questions, get personalized responses, and ensure your organization is prepared for the regulatory shifts ahead.

This webinar will discuss the widespread issue of physical inactivity and its biological underpinnings. Dr. Letsinger will provide an overview of the biological promoters of physical activity and how wheel-running mice are an effective model to better understand these mechanisms.

Ever since regulatory agencies globally mandate pediatric clinical trials for drugs intended for pediatric use, there has been a significant increase in the number of industrially sponsored pediatric clinical trials in recent years. This webinar examines the world of pediatric dosage forms and how orally disintegrating tablets (ODTs) are emerging as a specialized drug delivery system for children.Featured speakers include: Prof. Afzal Mohammed from Aston University, and Leon Grother, Formulation Manager at Catalent.

Discover a groundbreaking webinar delving into the importance of patient-centricity in hematological malignancy clinical trials. At the heart of every therapeutic breakthrough are patients — and their loved ones — whose noble contributions to medical research pave the path to market for innovative treatments that improve outcomes and quality of life. In hematological malignancies — where global incidence is increasing and the median age for most diseases is 65-70 years of age — a patient-centered mindset is essential for addressing and overcoming barriers to clinical trial participation for this fragile patient population. Increasingly, sponsors and regulators are emphasizing the importance of enhancing the patient experience in clinical trials to increase participation and generate meaningful data that truly reflects patients’ needs and preferences. When implemented successfully, patient-centric strategies promote higher engagement and, ultimately, improved healthcare outcomes. Join this webinar to gain insights into: Drivers and benefits of patient centricity in the clinical trial landscape, Why patient-centric approaches are important in populations with hematological malignancies, Regulatory perspectives on the patient experience in clinical trials, How to design and execute patient-centric hematological malignancy clinical trials, with real-life examples